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Background: The ePSOM development programme is a collaboration between the
University of Edinburgh and Alzheimer’s Research UK prompted by the recognition
that outcome measures currently used in clinical trials in prodromal and preclinical
neurodegenerative diseases do not capture the research participants’ views of effec-
tiveness. A better understanding of earlier manifestations of Alzheimer’s disease and
the drive for relevant outcome measures, allied to technological advances in artificial
intelligence, havemediated theelectronicPerson-SpecificOutcomeMeasure (ePSOM)
development programme. The group took the view that ‘maintenance of brain health’
as opposed to ‘avoidance of symptoms’ would form the underpinning narrative in the
ePSOMprogramme and ultimately app design.
Method: There are 4 sequential stages in the ePSOMprogramme (the first three com-
pleted): (1) literature review, (2) focus group study, (3) national survey, and (4) develop-
ment of an app for capturing person-specific outcomes. The survey data was analysed
using clustering and natural language programming techniques and the results are pre-
sented separately. Here, we report the overall approach to the ePSOMprogramme.
Result: Our literature review on patient-reported outcome measures in the
Alzheimer’s disease population showed trials currently do not use any patient-
reported outcome measures. Our focus groups with people living with memory
problems; healthy volunteers and health care professionals (n=41) yielded five key
domains in relation to what matters to people when developing new treatments for
Alzheimer’s disease: Everyday Functioning; Relationships and Social Connections;
Enjoying Life; Sense of Identity; and Alleviating Symptoms. Our online survey, which
was created based on the literature review and focus groups, was completed by 5807
individuals. 30 clusters of themes emerged from the survey responses.
Conclusion: The ePSOM development programme is building evidence in order to
deliver the methodology for incorporating personally meaningful outcome measures
in Alzheimer’s disease clinical trials. The completed three stages will underpin the
ePSOM app, which will be using natural language processing methodologies, and have
good psychometric properties enabling the app to be use in regulatory trials.
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